Green tea extract supplementation does not modify plasma concentration of F2-isoprostanes in women who are postmenopause: Findings from a randomized controlled trial

Jennifer R. Bathgate; Diane Rigassio Radler; Mindy Kurzer; Hamed Samavat

doi:10.1016/j.nutres.2023.03.001

Green tea extract supplementation does not modify plasma concentration of F₂-isoprostanes in women who are postmenopause: Findings from a randomized controlled trial

Jennifer R. Bathgate, Diane Rigassio Radler, Mindy Kurzer, Hamed Samavat

Food Science and Nutrition

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Green tea extract (GTE) is a potential mitigator of oxidative stress, and F₂-isoprostanes are a reliable biomarker of oxidative stress. Genetic polymorphisms in the catechol-o-methyltransferase (COMT) gene may modify tea catechin metabolism, prolonging exposure. We hypothesized that GTE supplementation would decrease plasma F₂-isoprostanes concentrations compared with placebo and that participants with the COMT genotype polymorphisms would experience a more significant expression of this outcome. This study was a secondary analysis of the Minnesota Green Tea Trial, a randomized placebo-controlled, double-blinded trial investigating the effects of GTE in women who were generally healthy and postmenopausal. The treatment group consumed 843 mg of epigallocatechin gallate daily for 12 months versus placebo. Participants in this study had a mean age of 60 years, were predominantly White, and most had a healthy body mass index. GTE supplementation did not significantly change plasma F₂-isoprostanes concentrations compared with placebo after 12 months (P for overall treatment = .07). There were no significant interactions between treatment and age, or body mass index, physical activity, smoking history, and alcohol intake. COMT genotype did not modify the effect of GTE supplementation on F₂-isoprostanes concentrations in the treatment group (P = .85). Among participants in the Minnesota Green Tea Trial, consuming GTE supplements daily for 1 year did not result in a significant decrease in plasma F₂-isoprostanes concentrations. Likewise, the COMT genotype did not modify the effect of GTE supplementation on F₂-isoprostanes concentrations.

Original language	English (US)
Pages (from-to)	29-38
Number of pages	10
Journal	Nutrition Research
Volume	113
DOIs	https://doi.org/10.1016/j.nutres.2023.03.001
State	Published - May 2023

Bibliographical note

Funding Information:
No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial.

Funding Information:
No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236 ). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial.

Publisher Copyright:
© 2023 Elsevier Inc.

Keywords

COMT genotype
Catechol-O-methyltransferase
F-isoprostanes
Green tea extract
Postmenopause
Women

PubMed: MeSH publication types

Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural

Access

10.1016/j.nutres.2023.03.001

OpenUrl availability

Full text

Cite this

@article{75a2761ef1834cb08f7d5bb80cb3f050,

title = "Green tea extract supplementation does not modify plasma concentration of F2-isoprostanes in women who are postmenopause: Findings from a randomized controlled trial",

abstract = "Green tea extract (GTE) is a potential mitigator of oxidative stress, and F2-isoprostanes are a reliable biomarker of oxidative stress. Genetic polymorphisms in the catechol-o-methyltransferase (COMT) gene may modify tea catechin metabolism, prolonging exposure. We hypothesized that GTE supplementation would decrease plasma F2-isoprostanes concentrations compared with placebo and that participants with the COMT genotype polymorphisms would experience a more significant expression of this outcome. This study was a secondary analysis of the Minnesota Green Tea Trial, a randomized placebo-controlled, double-blinded trial investigating the effects of GTE in women who were generally healthy and postmenopausal. The treatment group consumed 843 mg of epigallocatechin gallate daily for 12 months versus placebo. Participants in this study had a mean age of 60 years, were predominantly White, and most had a healthy body mass index. GTE supplementation did not significantly change plasma F2-isoprostanes concentrations compared with placebo after 12 months (P for overall treatment = .07). There were no significant interactions between treatment and age, or body mass index, physical activity, smoking history, and alcohol intake. COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations in the treatment group (P = .85). Among participants in the Minnesota Green Tea Trial, consuming GTE supplements daily for 1 year did not result in a significant decrease in plasma F2-isoprostanes concentrations. Likewise, the COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations.",

keywords = "COMT genotype, Catechol-O-methyltransferase, F-isoprostanes, Green tea extract, Postmenopause, Women",

author = "Bathgate, {Jennifer R.} and Radler, {Diane Rigassio} and Mindy Kurzer and Hamed Samavat",

note = "Funding Information: No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial. Funding Information: No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236 ). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = may,

doi = "10.1016/j.nutres.2023.03.001",

language = "English (US)",

volume = "113",

pages = "29--38",

journal = "Nutrition Research",

issn = "0271-5317",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Green tea extract supplementation does not modify plasma concentration of F2-isoprostanes in women who are postmenopause

T2 - Findings from a randomized controlled trial

AU - Bathgate, Jennifer R.

AU - Radler, Diane Rigassio

AU - Kurzer, Mindy

AU - Samavat, Hamed

N1 - Funding Information: No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial. Funding Information: No funding was received for this secondary analysis research study. The parent study was funded by a grant from the National Institutes of Health/National Cancer Institute (grant R01 CA127236 ). Support was financial only and the National Institutes of Health/National Cancer Institute did not have a role in study design or in the collection, analysis or interpretation of the data, or in writing the report or the decision to submit for publication. No additional funding was received for this secondary analysis of the Minnesota Green Tea Trial. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/5

Y1 - 2023/5

N2 - Green tea extract (GTE) is a potential mitigator of oxidative stress, and F2-isoprostanes are a reliable biomarker of oxidative stress. Genetic polymorphisms in the catechol-o-methyltransferase (COMT) gene may modify tea catechin metabolism, prolonging exposure. We hypothesized that GTE supplementation would decrease plasma F2-isoprostanes concentrations compared with placebo and that participants with the COMT genotype polymorphisms would experience a more significant expression of this outcome. This study was a secondary analysis of the Minnesota Green Tea Trial, a randomized placebo-controlled, double-blinded trial investigating the effects of GTE in women who were generally healthy and postmenopausal. The treatment group consumed 843 mg of epigallocatechin gallate daily for 12 months versus placebo. Participants in this study had a mean age of 60 years, were predominantly White, and most had a healthy body mass index. GTE supplementation did not significantly change plasma F2-isoprostanes concentrations compared with placebo after 12 months (P for overall treatment = .07). There were no significant interactions between treatment and age, or body mass index, physical activity, smoking history, and alcohol intake. COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations in the treatment group (P = .85). Among participants in the Minnesota Green Tea Trial, consuming GTE supplements daily for 1 year did not result in a significant decrease in plasma F2-isoprostanes concentrations. Likewise, the COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations.

AB - Green tea extract (GTE) is a potential mitigator of oxidative stress, and F2-isoprostanes are a reliable biomarker of oxidative stress. Genetic polymorphisms in the catechol-o-methyltransferase (COMT) gene may modify tea catechin metabolism, prolonging exposure. We hypothesized that GTE supplementation would decrease plasma F2-isoprostanes concentrations compared with placebo and that participants with the COMT genotype polymorphisms would experience a more significant expression of this outcome. This study was a secondary analysis of the Minnesota Green Tea Trial, a randomized placebo-controlled, double-blinded trial investigating the effects of GTE in women who were generally healthy and postmenopausal. The treatment group consumed 843 mg of epigallocatechin gallate daily for 12 months versus placebo. Participants in this study had a mean age of 60 years, were predominantly White, and most had a healthy body mass index. GTE supplementation did not significantly change plasma F2-isoprostanes concentrations compared with placebo after 12 months (P for overall treatment = .07). There were no significant interactions between treatment and age, or body mass index, physical activity, smoking history, and alcohol intake. COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations in the treatment group (P = .85). Among participants in the Minnesota Green Tea Trial, consuming GTE supplements daily for 1 year did not result in a significant decrease in plasma F2-isoprostanes concentrations. Likewise, the COMT genotype did not modify the effect of GTE supplementation on F2-isoprostanes concentrations.

KW - COMT genotype

KW - Catechol-O-methyltransferase

KW - F-isoprostanes

KW - Green tea extract

KW - Postmenopause

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85151237425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151237425&partnerID=8YFLogxK

U2 - 10.1016/j.nutres.2023.03.001

DO - 10.1016/j.nutres.2023.03.001

M3 - Article

C2 - 37011435

AN - SCOPUS:85151237425

SN - 0271-5317

VL - 113

SP - 29

EP - 38

JO - Nutrition Research

JF - Nutrition Research

ER -